Atai Life Sciences N.V., through its subsidiary, ATAI Life Sciences AG, operates as a clinical-stage biopharmaceutical company. It engages in developing various therapeutic candidates that focuses on various mental health disorders. The company's therapeutic candidates include PCN-101, a subcutaneous formulation of R-ketamine for the treatment of treatment-resistant depression (TRD); RL-007, a cholinergic, glutamatergic, and GABA-B receptor modulator to treat cognitive impairment associated with schizophrenia; DMX-1002, an oral formulation of ibogaine for treating opioid use disorder (OUD); GRX-917, an oral formulation of a deuterated version of etifoxine for the generalized anxiety disorder treatment; and NN-101, a novel intranasal formulation of N-acetylcysteine to treat mild traumatic brain injuries. Its therapeutic candidates also comprise VLS-01, a formulation of N,N-dimethyltryptamine for treating TRD; EMP-01, an oral formulation of an 3,4-methyl enedioxy methamphetamine for the treatment of post-traumatic stress disorder; RLS-01, a formulation of Salvinorin A for TRD; KUR-101, an oral formulation of deuterated mitragynine to treat OUD; and DMX-1001, an oral formulation of noribogaine for the treatment of OUD. The company was formerly known as Adripa Holding B.V. Atai Life Sciences N.V. was founded in 2018 and is headquartered in Berlin, Germany.

	Dec '19	Dec '20	Dec '21	Dec '22	Dec '23
revenue			20.38M -	233K 98.86%	314.00K 34.76%
cost of revenue					319.00K -
gross profit			20.38M -	233K 98.86%	-5K 102.15%
selling and marketing expenses					-1 -
general and administrative expenses	5.09M -	80.73M 1,486.13%	92.75M 14.88%	70.35M 24.15%	63.58M 9.62%
selling general and administrative expenses	5.09M -	80.73M 1,486.13%	92.75M 14.88%	70.35M 24.15%	63.58M 9.62%
research and development expenses	3.08M -	11.41M 269.91%	47.96M 320.37%	74.31M 54.96%	61.88M 16.73%
other expenses	425K -	-16.09M 3,886.12%	-796K 95.05%	9.61M 1,306.66%
cost and expenses	8.17M -	92.14M 1,027.26%	140.70M 52.70%	144.66M 2.82%	125.78M 13.05%
operating expenses	8.17M -	92.14M 1,027.26%	140.70M 52.70%	144.66M 2.82%	125.47M 13.27%
interest expense				1.92M -	-2.66M 238.69%
ebitda	1.58M -	-98.47M 6,332.09%	-104.84M 6.48%	-144.07M 37.42%	-125.15M 13.13%
operating income	1.57M -	-104.16M 6,717.66%	-135.81M 30.38%	-144.79M 6.61%	-125.47M 13.34%
depreciation and amortization	6K -	5.70M 94,816.67%	30.96M 443.63%	714K 97.69%	319.00K 55.32%
total other income expenses net	-19.05M -	2.35M 112.33%	-796K 133.89%	9.61M 1,306.66%	86.19M 797.29%
income before tax	-17.47M -	-101.81M 482.65%	-136.60M 34.17%	-135.18M 1.04%	-39.29M 70.94%
income tax expense	2K -	305K 15,150%	-3.99M 1,407.87%	6.23M 256.15%	1.02M 83.69%
net income	-17.48M -	-102.12M 484.33%	-132.61M 29.86%	-141.41M 6.64%	-40.22M 71.56%
weighted average shs out	152.57M -	152.57M 0%	138.27M 9.38%	155.72M 12.62%	158.83M 2.00%
weighted average shs out dil	152.57M -	152.57M 0%	138.27M 9.38%	155.72M 12.62%	158.83M 2.00%
eps	-0.11 -	-0.67 509.09%	-0.96 43.28%	-0.91 5.21%	-0.25 72.53%
epsdiluted	-0.11 -	-0.67 509.09%	-0.96 43.28%	-0.91 5.21%	-0.25 72.53%

LIFE:ATAI

atai Life Sciences

Last Close

1.52

22/11 21:00

Market Cap

220.98M

Beta: -

Volume Today

2.09M

Avg: -

Preview